linjc16/ctgov huggingface dataset:
Assessment of Decision Support System Software in Extraction and Anchorage Planning Among Adult Patients Using Computer Algorithm

Study Overview
=================
Brief Summary
-----------------
It was introduced in dentistry to be used in innovative research and development in addition to facilitating the decision in complicated cases and ensure high patient care quality. In the field of Orthodontics in specific, many studies previously mentioned the idea of artificial intelligence showing very promising results and high degree of reliability. It was used in different domains in orthodontics like diagnosis, treatment planning, evaluation of treatment outcome

Detailed Description
-----------------
In this study, the aim is to access the efficiency of the new decision support system in determining whether the decision is extraction or non-extraction and the anchorage plan required for each case. This was performed in the past in many countries and those studies are published

Official Title
-----------------
Assessment of Decision Support System Software in Extraction and Anchorage Planning Among Adult Patients Using Computer Algorithm

Conditions
-----------------
Cases That Need Extraction of Teeth in Orthodontics, Anchorage Planning

Intervention / Treatment
-----------------
* Other: Well finished cases


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cases with well finished orthodontic treatment. Cases with history of crowding more than 10 mm and requiring extraction. Cases with no severe skeletal discrepancy. Well documented cases with both pre-operative and post-operative records. Patients with a full set of permanent teeth erupted Exclusion Criteria: Improperly finished orthodontic cases. Cases with mild crowding managed by treatment options other than extraction. Growing patients or showing any residual growth remaining in cephalometric analysis Cases with severe skeletal discrepancy. Poorly documented cases. Patients not sticking to anchorage plan

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| well fininshed cases<br> | Other: Well finished cases<br>* To decide whether extraction or non-extraction decision will be made for each case<br>* Other names: extraction and non-extraction in well finished cases;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To study the efficiency of the program decisions in terms of extraction/non-extraction and Anchorage planning decisions | The concordance correlation coefficient would be used to measure the agreement between the 2 methods on the basis of the values (%) assigned for each treatment option by the 2 methods (quantitative data). | 1 year |
Effect on Tear Functions of Pretarsal and Preseptal Techniques of Botulinum Toxin Type A Injection in Hemifacial Spasm

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether pretarsal and preseptal techniques of Botulinum toxin type A injection have any effect on tear functions.

Detailed Description
-----------------
Botulinum toxin type A has been used for hemifacial spasm since 1986. of Botulinum toxin type A can be subcutaneously injected at pretarsal or preseptal portion of orbicularis muscle. Blepharoptosis has been reported less frequently with pretarsal technique, however dry eye was noticed in one patient treated with pretarsal botulinum toxin type A for cosmetic purpose.

Official Title
-----------------
Effect on Tear Functions of Pretarsal and Preseptal Techniques of Botulinum Toxin Type A Injection in Hemifacial Spasm

Conditions
-----------------
Hemifacial Spasm

Intervention / Treatment
-----------------
* Drug: preseptal injection of botulinum toxin type A
* Drug: pretarsal injection of Botulinum toxin type A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient diagnosed with hemifacial spasm Exclusion Criteria: previous history of botulinum toxin treatment for hemifacial spasm ocular surface disorders tear disorders evidence of infection at or around eyelids pregnant woman other neurologic disease, i.e. OMG coagulopathy or treatment with thrombolytic agent treatment with aminoglycosides, chloroquine, hydroxychloroquine

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: preseptal<br> | Drug: preseptal injection of botulinum toxin type A<br>* botulinum toxin type A (Botox)2.5 units, 5 points<br>* Other names: Botox;|
| Experimental: pretarsal<br> | Drug: pretarsal injection of Botulinum toxin type A<br>* Botulinum toxin type A 2,5 units, 5 points<br>* Other names: Botox;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| tear break up time | unit of measure; minutes | change from baseline in tear break up time at 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| schirmer's test | units of measurement; millimeters | change from baseline of schirmer's test at 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
botulinum toxin, facial nerve, hemifacial spasm, tears
Incidence and Risk Factor of Hydroxychloroquine and Chloroquine Retinopathy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the incidence and risk factor of toxic maculopathy who treated with hydroxychloroquine or chloroquine due to their autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus. Total 5-year of the study periods, the investigators will screen these patients by baseline examination (Fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography) and observe with same examination for every year.

Official Title
-----------------
Incidence and Risk Factor Evaluation for Toxic Maculopathy Associated With Hydroxychloroquine and Chloroquine

Conditions
-----------------
Toxic Maculopathy

Intervention / Treatment
-----------------
* Procedure: Composite Examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who treated with HCQ or CQ due to autoimmune diseases such as RA, SLE Patient who did not previously diagnosed with HCQ/CQ toxic retinopathy Exclusion Criteria: Aged less than 19 years

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HCQ/CQ<br>Patients who treated with HCQ(Hydroxychloroquine) or CQ(Chloroquine) for autoimmune diseases such as Rheumatoid arthritis(RA), systemic lupus erythematosus(SLE) will be recruited, and get the composite examination for toxic maculopathy. | Procedure: Composite Examination<br>* First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of toxic maculopathy associated with HCQ or CQ |  | 1 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factor of HCQ/CQ retinopathy |  | 5 years | 
| Characteristics and type of HCQ/CQ retinopathy (parafoveal or pericentral retinopathy) |  | 5 years | 
| Progression of retinopathy after drug cessation |  | 1 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Autoimmune Disease, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Hydroxychloroquine(HCQ), Chloroquine(CQ), Toxic Maculopathy
Brief Intervention to Reduce Drinking Among Batterers

Study Overview
=================
Brief Summary
-----------------
The goal of this project is to examine whether, relative to standard care, violence and alcohol use outcomes can be improved by a brief, motivationally based adjunct alcohol treatment for men enrolled in batterer intervention programs. We hypothesize that men randomized to also receive the brief alcohol intervention will have better partner violence and alcohol use outcomes than men who are randomized to the batterer intervention program alone.

Official Title
-----------------
Brief Intervention to Reduce Drinking Among Batterers

Conditions
-----------------
Intimate Partner Violence, Alcohol Use

Intervention / Treatment
-----------------
* Behavioral: Standard Batterer Intervention
* Behavioral: Brief Alcohol Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participation in a batterer intervention program Hazardous drinking
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>Standard 40 hour state-mandated batterer intervention | Behavioral: Standard Batterer Intervention<br>* Standard state-mandated batterer intervention program (40 hours)<br>|
| Other: 2<br>Brief alcohol intervention combined with standard batterer intervention | Behavioral: Brief Alcohol Intervention<br>* Brief alcohol intervention combined with state mandated batterer intervention program<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intimate partner violence Substance use |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intimate partner violence, alcohol use, substance use
Mechanisms of Myocardial Infarction in Women With Non Obstructive Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
The objective of our work to determine the mechanisms of myocardial infarction in women without obstructive coronary artery disease.

Detailed Description
-----------------
Cardiovascular disease is the leading cause of death for women. Acute coronary syndrome (ACS) is usually characterized by a sudden erosion of the endothelial wall or rupture of a plaque.However, women with ACS are less likely than men to have either classic symptoms or obstructive coronary artery disease but paradoxically have a worse prognosis. Different data from the literature indicate that there may be different pathophysiological mechanisms, afflicting men and women somewhat differently.Between 5% and 30% of patients with ACS undergoing coronary angiography are found to have non visible or non obstructive coronary disease (NOCD). This is 2-3 times more common in women than in men. Several pathogenetic mechanism of myocardial infarction (MI) in the absence of obstructive coronary artery disease (OCD) have been postulated, including among others atherosclerosis with plaque disruption that does not lead to luminal occlusion ,endothelial dysfunction, vasospasm , distal microembolization and microvascular dysfunction. However the data are extremely limited.

Official Title
-----------------
Mechanisms of Myocardial Infarction in Women With Non Obstructive Coronary Artery Disease

Conditions
-----------------
Myocardial Infarction

Intervention / Treatment
-----------------
* Procedure: cardiac imajing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women ≥ 18 years old, not pregnant with acute non ST elevation myocardial infarction (admitted within 12 hours from beginning of symptoms) who are candidates for coronary arteriography during the hospitalization. - Exclusion Criteria: *Women with troponin elevation caused by other causes -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| non obstructive coronary disease<br>non obstructive coronary disease | Procedure: cardiac imajing<br>* Cardiac MRI<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MORTALITY |  | 1 YEAR |
Ultrasound Guided Positioning of Central Venous Catheters

Study Overview
=================
Brief Summary
-----------------
The current standard for (correct) position control of a central venous catheter (CVC) is X-ray control, which is associated with X-rays for the patient. In some clinics, radiological services are not offered around the clock. Therefore, an alternative that is not burdensome for patients and is available on all sides would be desirable. The possibility of a sonographic CVC position control is to be investigated. The correct position of a central venous catheter is important. Complications/failure must be detected early/immediately. In addition to the X-ray of the thorax, a position control by means of an ECG derivative (α-card derivative) is available for position control. The method is easy to perform, but an epicardial or an arterial position of the CVC cannot be detected without the use of additional imaging in case of doubt. For the reasons mentioned above, sonography is a suitable method to show the inflow of injected 0.9% sodium chloride solution into the right atrium, which allows to conclude the correct position of the CVC.

Official Title
-----------------
Ultrasound Guided Positioning of Central Venous Catheters

Conditions
-----------------
Central Venous Catheter

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective insertion of a central venous catheter. Exclusion Criteria: emergency insertion of a central venous catheter

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Ultrasound<br> | Diagnostic Test: Ultrasound<br>* Using ultrasound control, the central vein catheter is injected with saline solution and the time to detect the saline bolus in the ultrasound is measured.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| - correlation between the time of detection of the injected saline bolus and radiological position of the central venous catheter | - ultrasound during injection of saline solution into a newly inserted central venous catheter | up to 5 seconds |
Stroke Observatory of Caen-Normandie Metropole

Study Overview
=================
Brief Summary
-----------------
Stroke Observatory of Caen-Normandy Metropole provides epidemiological data in prospective collection. The primary objective is to determinate incidence of Stroke in this area. Several data sources will be crossed to allow an exhaustive identification of the cases. No intervention will be carried. The data collected will correspond to those obtained in current practice. The number of participants is estimated at 800 per year. This Observatory aims to become a qualified population register after three years, according to requirement of the french registry evaluation committee.

Detailed Description
-----------------
Stroke is the second leading cause of death (the first in women in industrialized countries), the second cause of dementia and the third leading cause of disability. For a middle-aged person, the risk of developing a stroke is 1/5 in women and 1/6 in men over a lifetime. Moreover, stroke is a disease that can be considered chronic. Indeed, in France, the survival rate one month after a stroke is 80-90%. However, at least 50% of survivors retain a severe disability and almost all require long-term care. The medico-economic impact of stroke is therefore important in both the initial and chronic phases. Nevertheless, none of the French stroke registries consider the burden of post-stroke disability. In addition, there is limited data available on the impact of geographic disparities on the prognosis of stroke. Population studies are essential to accurately identify the incidence and burden of stroke, thereby supporting public health policy, guiding the allocation of resources, and evaluating the effectiveness of preventive strategies for a population. This is why we propose to create a Norman Observatory of Stroke. It will include an urban and rural population and will aim to become a population register.

Official Title
-----------------
Stroke Observatory of Caen-Normandie Metropole

Conditions
-----------------
Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any types of strokes (initial, recidivism) Place of residence in Caen-Normandie Metropole Age higher than 30 days (exclusion of perinatal stroke) Exclusion Criteria: None, unless patient opposition

Ages Eligible for Study
-----------------
Minimum Age: 30 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stroke incidence in Caen-Normandy Metropole | To determinate the incidence of stroke in Caen-Normandy Metropole | 15 may 2017 to 15 may 2020 | 
| Stroke acute mortality in Caen-Normandy Metropole | To determinate the incidence of Stroke acute mortality | 15 may 2017 to 15 may 2020 |
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice

Study Overview
=================
Brief Summary
-----------------
This observational, multi-center study will evaluate the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in renal anemia correction in dialysed patients in daily clinical practice. Patient will receive Mircera according to local summary of product characteristics. Data will be collected for 12 months.

Official Title
-----------------
Non-interventional Study to Assess the Efficacy of Mircera for Renal Anemia Correction in Dialysis Patients in Everyday Clinical Practice in Poland.

Conditions
-----------------
Anemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients, >/=18 years of age Adequate iron status Signed informed consent form Exclusion Criteria: Anemia due to non-renal causes Where investigator considers the patient unsuitable for inclusing for other reasons (e.g. severe co-morbidities as active bleeding, infections or cancer) Pregnant or lactating female patients Any contraindications against treatment with Mircera (according to local Summary of Product Characteristics)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients who achieve a hemoglobin level of >/=10 g/dl |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety: incidence of adverse events |  | 12 months |